Menu
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
DIA/FDA Advancing Complex Innovative Clinical Trial Designs to Efficiently Deliver Medicines to Patients
Session 3: Flexible, Efficient Decision-Making: Complex Adaptive Design
Session Chair(s)
Yi Liu, PhD
- Executive Director Biostatistics
- Nektar Therapeutics, United States
Cristiana Mayer, DrSc, PhD
- Head of Biostatistics
- Johnson & Johnson Vision, United States

Gregory Levin, PhD
- Deputy Director, DBIII, OB, OTS, CDER
- FDA, United States
Novel methods for planning decision-making in Complex Innovative Designs comprise different features of adaptive efficient trials. Efficiency can be viewed from different angles to balance correct decision-making as early as possible for a drug development program with cost-effectiveness and quantification of multiple metrics to measure “success” of a trial. An example of a platform trial in the infectious disease area is presented to illustrate a Bayesian approach to utilize longitudinal data for developing a predictive model for the long-term clinical outcome. In confirmatory settings, the use of a basket trial will be used to illustrate the effect of adaptive trials on cost-effectiveness and feasibility of drug development in rare diseases and/or subgroups of common diseases like cancer. A third presentation will address an optimal sample size adaptation rule that maximizes return on investment, a metric to balance time to market, trial costs, and probability of success.
Learning Objective :
At the conclusion of this session, participants should be able to:
- Understand essential elements of decision-making in the context of complex adaptive designs
- Recognize different methods and applications of adaptive designs
- Appreciate complexity of decision-making in drug development
Speaker(s)
Speaker
Cesar Daniel Torres, PhD, MS
- Mathematical Statistician
- FDA, United States
Improving Efficiencies in Drug Development Through a Platform Trial
J. Kyle Wathen, PhD, MS
- Senior Director, Advanced Analytics
- Gilead Sciences, Inc. , United States
Efficiency and Type I Error Control of a Generalized Confirmatory Basket Trial Design
Robert A. Beckman, MD
- Professor of Oncology, Bioinformatics, and Biomathematics
- Georgetown University Medical Center, United States
Complex Sample Size Re-Estimation Designs in Pivotal Trials and its Impact on Return on Investment
Yi Liu, PhD
- Executive Director Biostatistics
- Nektar Therapeutics, United States

Panelist
Gregory Levin, PhD
- Deputy Director, DBIII, OB, OTS, CDER
- FDA, United States

Panelist
Nora E Carbine
- Georgetown Breast Cancer Advocate
- Georgetown Lombardi Cancer Center , United States
Contact us
Registration Questions?
Additional Information
Complex Innovative Clinical Trial Designs Resource Kit
View Infographic
On Demand Content Preview Webinar
Recent Regulatory Efforts on Complex Innovative Clinical Trial Design
Register Today!